Trials / Completed
CompletedNCT01251718
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 894 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the clinical safety and effectiveness of donepezil hydrochloride administration in patients with mild or moderate Alzheimer's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | donepezil hydrochloride | Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2015-10-14
- Completion
- 2016-02-18
- First posted
- 2010-12-02
- Last updated
- 2023-07-24
Locations
106 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01251718. Inclusion in this directory is not an endorsement.